Astria Therapeutics, Inc. – NASDAQ:ATXS

Add to watchlist

$6.3

-2.85

-31.15%

Market open

Closed in about 1 hour

-20.16%

month

-20.16%

quarter

+16.41%

year

Market Cap	528.22M
Enterprise value	147.65M

P/E	-3.73
EV/Sales	N/A
EV/EBITDA	-2.88
Price/Sales	N/A
Price/Book	0.75
PEG ratio	-0.04
EPS	-2.32

Revenue	N/A
EBITDA	-78.48M
Income	-81.63M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Astria Therapeutics, Inc. (NASDAQ:ATXS): Profit margin
Jun 2023	0	-12.56M
Sep 2023	0	-17.72M
Dec 2023	0	-31.41M
Mar 2024	0	-19.92M

Astria Therapeutics Financials Estimate

Q Y

Astria Therapeutics, Inc. (NASDAQ:ATXS): Analyst Estimates
Mar 2024	0	-19.92M
Sep 2025	0	-13.14M
Oct 2025	0	-23.27M
Dec 2025	0	-22.74M

Analysts Price target
Financials & Ratios estimates

Astria Therapeutics, Inc. (NASDAQ:ATXS): Debt to assets
Jun 2023	207053000	6.65M	3.21%
Sep 2023	193861000	9.38M	4.84%
Dec 2023	254666000	11.55M	4.54%
Mar 2024	378807000	11.07M	2.92%

Astria Therapeutics, Inc. (NASDAQ:ATXS): Cash Flow
Jun 2023	-10.69M	-57.92M	273K
Sep 2023	-14.25M	-4K	110K
Dec 2023	-30.23M	-2.01M	87.97M
Mar 2024	-19.09M	-126.23M	141.80M

Astria Therapeutics alternative data

Astria Therapeutics, Inc. (NASDAQ:ATXS): Employee count
Aug 2023	45
Sep 2023	45
Oct 2023	45
Nov 2023	45
Dec 2023	45
Jan 2024	45
Feb 2024	45
Mar 2024	59
Apr 2024	59
May 2024	59
Jun 2024	59
Jul 2024	59

Astria Therapeutics
Hedge Funds Holdings Q1 2023

41.66% -58.34%

of ATXS is owned by hedge funds

23 -38

hedge funds hold ATXS stock

6.09M -15.87M

shares is hold by hedge funds

ATXS hedge funds holdings changes

Astria Therapeutics
Insider Trading

Astria Therapeutics, Inc. (NASDAQ:ATXS): Insider trades (number of shares)
Period	Buy	Sel
Oct 2023	3991402	0
Dec 2023	740000	0
Jan 2024	0	10000
Feb 2024	2481350	0
Apr 2024	0	10000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	1 Apr 2024	MORABITO CHRISTOPHER officer: Chief Medical Officer officer: Chief Medical Officer	Stock Option (Right to Buy)	10,000	$3.87	$38,700
Option	1 Apr 2024	MORABITO CHRISTOPHER officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	10,000	$3.87	$38,700
Sale	1 Apr 2024	MORABITO CHRISTOPHER officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	10,000	$13.59	$135,940
Purchase	1 Feb 2024	PERCEPTIVE ADVISORS LLC director director	Common Stock	2,481,350	$12.09	$29,999,522
Option	29 Jan 2024	MORABITO CHRISTOPHER officer: Chief Medical Officer officer: Chief Medical Officer	Stock Option (Right to Buy)	9,200	$3.87	$35,604
Option	29 Jan 2024	MORABITO CHRISTOPHER officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	9,200	$3.87	$35,604
Sale	29 Jan 2024	MORABITO CHRISTOPHER officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	9,200	$11.15	$102,552
Option	26 Jan 2024	MORABITO CHRISTOPHER officer: Chief Medical Officer officer: Chief Medical Officer	Stock Option (Right to Buy)	800	$3.87	$3,096
Option	26 Jan 2024	MORABITO CHRISTOPHER officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	800	$3.87	$3,096
Sale	26 Jan 2024	MORABITO CHRISTOPHER officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	800	$11.02	$8,812

ATXS insider trading transactions

Astria Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q3 2023 13 Nov 2023	Q3 2023 Earnings Call Transcript
Q4 2022 22 Mar 2023	Q4 2022 Earnings Call Transcript
Q3 2021 10 Nov 2021	Q3 2021 Earnings Call Transcript

ATXS earnings call transcripts

Astria Therapeutics
Executives

Insider	Age	Since	Compensation
Ms. Jill C. Milne Ph.D. (1968) Co-Founder, Chief Executive Officer, Pres & Director	57		$716,960
Dr. Andrew J. Nichols Ph.D. (1961) Chief Scientific Officer	64		$544,240

Astria Therapeutics
Latest News

Tuesday, 17 December 2024
10:40	Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?	zacks.com
Tuesday, 3 December 2024
16:10	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Wednesday, 27 November 2024
08:00	Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema	seekingalpha.com
Wednesday, 13 November 2024
16:10	Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update	businesswire.com
Wednesday, 2 October 2024
16:10	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Friday, 27 September 2024
08:00	Astria Therapeutics to Present at Upcoming Global Angioedema Forum	businesswire.com
Thursday, 19 September 2024
08:00	Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress	businesswire.com
Wednesday, 4 September 2024
16:10	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Thursday, 29 August 2024
08:00	Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference	businesswire.com
Tuesday, 4 June 2024
16:10	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Thursday, 30 May 2024
08:00	Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference	businesswire.com
Friday, 24 May 2024
08:00	Astria Therapeutics to Present at Upcoming Eastern Allergy Conference	businesswire.com
Thursday, 23 May 2024
08:00	Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress	businesswire.com
Thursday, 9 May 2024
16:10	Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update	businesswire.com
Wednesday, 8 May 2024
08:00	Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting	businesswire.com
Wednesday, 3 April 2024
16:10	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Monday, 25 March 2024
07:30	Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE	businesswire.com
Tuesday, 5 March 2024
16:10	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Monday, 4 March 2024
16:10	Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	businesswire.com
Tuesday, 20 February 2024
08:00	Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting	businesswire.com
Monday, 12 February 2024
08:53	Another Huge Buffett Purchase Highlights Recent Insider Buying	247wallst.com
Monday, 5 February 2024
16:00	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Tuesday, 30 January 2024
09:08	Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering	businesswire.com
Sunday, 31 December 2023
10:10	Here's What Insiders Are Buying to Wrap Up the Year	24/7 Wall Street
Monday, 13 November 2023
13:45	Astria Therapeutics, Inc. (ATXS) Q3 2023 Earnings Call Transcript	Seeking Alpha
Friday, 3 November 2023
08:10	Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting	Business Wire
Thursday, 12 October 2023
09:33	Astria Therapeutics strikes exclusive license agreement for dermatitis treatment portfolio	Proactive Investors
Tuesday, 19 September 2023
08:00	Astria Therapeutics: Too Much Baggage, Too Strong A Competition	Seeking Alpha
Friday, 21 July 2023
09:12	Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug	Zacks Investment Research
Friday, 14 July 2023
08:00	Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit	Business Wire

Ideas & Opinions

Seeking Alpha 19 Sep 2023

Astria Therapeutics: Too Much Baggage, Too Strong A Competition
Seeking Alpha 24 Apr 2023

Astria: Biotech To Watch With Proof Of Concept Established For HAE
Seeking Alpha 22 Feb 2023

BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
Seeking Alpha 25 Jan 2023

KalVista Pharmaceuticals: The Share Price Rally Requires An Adjustment Of My Investment Thesis
Seeking Alpha 24 Dec 2022

Astria Therapeutics: Tailwinds Building With Novel Treatment Paradigm
Seeking Alpha 14 Oct 2022

KalVista: Another Setback But The Key Value Driver Is Still In Place

Frequently Asked Questions (FAQ)

What's the price of Astria Therapeutics stock today?

One share of Astria Therapeutics stock can currently be purchased for approximately $6.3.
When is Astria Therapeutics's next earnings date?

Unfortunately, Astria Therapeutics's (ATXS) next earnings date is currently unknown.
Does Astria Therapeutics pay dividends?

No, Astria Therapeutics does not pay dividends.
How much money does Astria Therapeutics make?

Astria Therapeutics has a market capitalization of 528.22M.
What is Astria Therapeutics's stock symbol?

Astria Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ATXS".
What is Astria Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Astria Therapeutics?

Shares of Astria Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Astria Therapeutics's key executives?
Astria Therapeutics's management team includes the following people:
- Ms. Jill C. Milne Ph.D. Co-Founder, Chief Executive Officer, Pres & Director(age: 57, pay: $716,960)
- Dr. Andrew J. Nichols Ph.D. Chief Scientific Officer(age: 64, pay: $544,240)
Is Astria Therapeutics founder-led company?

Yes, Astria Therapeutics is a company led by its founder Ms. Jill C. Milne Ph.D..
How many employees does Astria Therapeutics have?

As Jul 2024, Astria Therapeutics employs 59 workers.
When Astria Therapeutics went public?

Astria Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 25 Jun 2015.
What is Astria Therapeutics's official website?

The official website for Astria Therapeutics is astriatx.com.
Where are Astria Therapeutics's headquarters?

Astria Therapeutics is headquartered at 100 High Street, Boston, MA.
How can i contact Astria Therapeutics?

Astria Therapeutics's mailing address is 100 High Street, Boston, MA and company can be reached via phone at +61 73491971.

Astria Therapeutics, Inc.

astriatx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

+61 73491971

100 High Street
Boston, MA 02110

CIK: 0001454789
ISIN: US04635X1028
CUSIP: 04635X102